Simulations Plus to Participate in Upcoming Investor Conferences
AI Sentiment
Positive
6/10
as of 02-05-2026 3:53pm EST
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 418.4M | IPO Year: | 1997 |
| Target Price: | $25.00 | AVG Volume (30 days): | 374.0K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.39 - $37.66 | Next Earning Date: | 01-08-2026 |
| Revenue: | $78,676,000 | Revenue Growth: | 5.70% |
| Revenue Growth (this year): | 2.64% | Revenue Growth (next year): | 6.01% |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | 23.0M | FCF Growth: | +104.83% |
Director
Avg Cost/Share
$16.91
Shares
866
Total Value
$14,644.06
Owned After
9,968
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| LaVange Lisa | SLP | Director | Dec 1, 2025 | Sell | $16.91 | 866 | $14,644.06 | 9,968 |
SLP Breaking Stock News: Dive into SLP Ticker-Specific Updates for Smart Investing
AI Sentiment
Positive
6/10
See how SLP stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "SLP Simulations Plus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.